ArticleInfectious diseases of poverty2026
Impact of COVID-19 on neglected tropical diseases in Zambia: a qualitative study of stakeholder perspectives.
Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeglected tropical diseases (NTDs) remain a major public health challenge in Zambia and other low‑ and middle‑income countries, and there is concern that the COVID‑19 pandemic has further disrupted progress towards control and elimination targets. This study explored how COVID‑19 affected NTD programmes, funding, and partnerships in Zambia from the perspective of national‑level stakeholders.
methodsWe conducted a qualitative case study using semi‑structured interviews with key informants involved in NTD policy, programming, or surveillance in Zambia. Fourteen participants were purposively sampled from government ministries, the Zambia National Public Health Institute, international organisations, and academia. Interviews were conducted in person, audio‑recorded, transcribed verbatim, and anonymised. Data were analysed using inductive thematic analysis, with codes developed from the transcripts and iteratively grouped into themes through constant comparison.
resultsFive overarching themes were identified: (1) public health infrastructure; (2) disease prioritisation and surveillance; (3) resource allocation and funding challenges; (4) collaboration and partnerships; and (5) direct impacts of COVID‑19 on NTD activities. Participants reported that COVID‑19 exposed and intensified pre‑existing weaknesses in health system capacity, routine NTD surveillance, and financing, contributing to delays and reduced coverage of mass drug administration (MDA) and other interventions. Donor funding reallocation and the withdrawal or scaling back of some international partners created further uncertainty for NTD programmes, although various national institutions and the World Health Organization (WHO) helped sustain essential activities. At the same time, the pandemic period coincided with the strengthening of the Zambia National Public Health Institute and the development of updated NTD and One Health strategic plans. Stakeholders viewed these institutional changes as opportunities to build a more resilient NTD response.
conclusionsCOVID‑19 disrupted NTD programmes in Zambia primarily by amplifying long‑standing structural vulnerabilities in funding, surveillance, and service delivery, rather than through complete programme collapse. Strengthening routine NTD data systems, securing more predictable domestic financing, operationalising One Health and NTD master plans, and building more resilient, locally owned partnerships will be essential to recover lost ground and protect NTD control efforts from future shocks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.